Minimal clinically important difference on the Motor Examination part of MDS-UPDRS

Parkinsonism and Related Disorders

Volumn 21, Issue 12, 2015, Pages 1421-1426

  Horváth, Krisztina ^a   Aschermann, Zsuzsanna ^a   Ács, Péter ^a   Deli, Gabriella ^a   Janszky, József ^a   Komoly, Sámuel ^a   Balázs, Éva ^a   Takács, Katalin ^a   Karádi, Kázmér ^a   Kovács, Norbert ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Clinician reported outcome; Minimal clinically important change; Minimal clinically important difference; Receiver operating characteristic curve; UPDRS

Indexed keywords

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE COURSE; FEMALE; HEALTH CARE CONCEPTS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; MOTOR DYSFUNCTION ASSESSMENT; MOVEMENT DISORDERS SOCIETY SPONSORED UNIFIED PARKINSON DISEASE RATING SCALE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84955642811     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.10.006     Document Type: Article

References (29)

1. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin. Trials 1989, 10:407-415.
2. Hauser R.A., Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov. Disord. 2011, 26:813-818.
3. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., Fishman P.S., Reich S.G., Weiner W.J. The clinically important difference on the unified Parkinson's disease rating scale. Arch. Neurol. 2010, 67:64-70.
4. Hauser R.A., Gordon M.F., Mizuno Y., Poewe W., Barone P., Schapira A.H., et al. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014, 2014:467131.
5. Revicki D., Hays R.D., Cella D., Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J. Clin. Epidemiol. 2008, 61:102-109.
6. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008, 23:2129-2170.
7. Martinez-Martin P., Chaudhuri K.R., Rojo-Abuin J.M., Rodriguez-Blazquez C., Alvarez-Sanchez M., Arakaki T., et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS scale. Eur. J. Neurol. 2015, 22:37-43.
8. Rodriguez-Blazquez C., Rojo-Abuin J.M., Alvarez-Sanchez M., Arakaki T., Bergareche-Yarza A., Chade A., et al. The MDS-UPDRS part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat. Disord. 2013, 19:889-893.
9. Lang A.E., Eberly S., Goetz C.G., Stebbins G., Oakes D., Marek K., et al. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov. Disord. 2013, 28:1980-1986.
10. Buck P.O., Trautman H., Clark J. Scales for assessing nonmotor symptom severity changes in Parkinson's disease patients with symptom fluctuations. Int. J. Neurosci. 2010, 120:523-530.
11. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Kahan J., Ell P., et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 2014, 4:337-344.
12. Chou K.L., Taylor J.L., Patil P.G. The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat. Disord. 2013, 19:966-969.
13. Deli G., Aschermann Z., Acs P., Bosnyak E., Janszky J., Faludi B., et al. Bilateral subthalamic stimulation can improve sleep quality in Parkinson's disease. J. Parkinsons Dis. 2015 Jun 1, 5(2):361-378. 10.3233/JPD-150540.
14. Kaszas B., Kovacs N., Balas I., Kallai J., Aschermann Z., Kerekes Z., et al. Sensitivity and specificity of Addenbrooke's Cognitive examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:553-556.
15. Lucza T., Karadi K., Kallai J., Weintraut R., Janszky J., Makkos A., et al. Screening mild and major neurocognitive disorders in Parkinson's Disease. Behav. Neurol. 2015, 2015:983606.
16. Lucza T., Karadi K., Komoly S., Janszky J., Kallai J., Makkos A., et al. Neurocognitive disorders in Parkinson's disease. Orv. Hetil. 2015, 156:915-926.
17. Horváth K., Aschermann Z., Ács P., Bosnyák E., Deli G., Pál E., et al. Validation of the Hungarian MDS-UPDRS: why do we need a new Parkinson scale?. Ideggyogy Sz 2014, 67:129-134.
18. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 2004, 19:1020-1028.
19. Busner J., Targum S.D. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007, 4:28-37.
20. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Earlbaum Associates, Hillsdale, NJ. second ed.
21. Samsa G., Edelman D., Rothman M.L., Williams G.R., Lipscomb J., Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999, 15:141-155.
22. Stebbins G., Goetz C.G., Siomkus V. Minimal clinically important change and the MDS-UPDRS motor examination. Mov. Disord. 2009, 24:S436.
23. Schrag A., Sampaio C., Counsell N., Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov. Disord. 2006, 21:1200-1207.
24. Soileau M.J., Persad C., Taylor J., Patil P.G., Chou K.L. Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: an exploratory analysis. J. Parkinsons Dis. 2014, 4:517-521.
25. Kovacs N., Aschermann Z., Acs P., Bosnyak E., Deli G., Janszky J., et al. The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease. Ideggyogy Sz 2014, 67:245-250.
26. Rose M.H., Lokkegaard A., Sonne-Holm S., Jensen B.R. Improved clinical status, quality of life, and walking capacity in Parkinson's disease after body weight-supported high-intensity locomotor training. Arch. Phys. Med. Rehabil. 2013, 94:687-692.
27. Duncan R.P., Earhart G.M. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil. Neural Repair 2012, 26:132-143.
28. Rios Romenets S., Anang J., Fereshtehnejad S.M., Pelletier A., Postuma R. Tango for treatment of motor and non-motor manifestations in Parkinson's disease: a randomized control study. Complement. Ther. Med. 2015, 23:175-184.
29. Kapur S.S., Stebbins G.T., Goetz C.G. Vibration therapy for Parkinson's disease: charcot's studies revisited. J. Parkinsons Dis. 2012, 2:23-27.